StockNews.com Initiates Coverage on Nymox Pharmaceutical (NASDAQ:NYMX)

StockNews.com initiated coverage on shares of Nymox Pharmaceutical (NASDAQ:NYMXGet Rating) in a report published on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Nymox Pharmaceutical Price Performance

Shares of NYMX stock opened at $0.37 on Monday. Nymox Pharmaceutical has a 1-year low of $0.19 and a 1-year high of $2.27. The firm has a fifty day moving average of $0.40 and a two-hundred day moving average of $1.09. The firm has a market cap of $33.77 million, a P/E ratio of -2.08 and a beta of 1.00.

Nymox Pharmaceutical (NASDAQ:NYMXGet Rating) last announced its quarterly earnings data on Friday, May 13th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter.

Institutional Trading of Nymox Pharmaceutical

A number of institutional investors and hedge funds have recently modified their holdings of NYMX. Citigroup Inc. bought a new stake in shares of Nymox Pharmaceutical during the 1st quarter valued at about $137,000. Murchinson Ltd. bought a new position in shares of Nymox Pharmaceutical during the first quarter valued at approximately $96,000. WMS Partners LLC acquired a new stake in shares of Nymox Pharmaceutical during the 1st quarter worth approximately $53,000. MAI Capital Management bought a new stake in shares of Nymox Pharmaceutical in the 1st quarter worth approximately $44,000. Finally, Patriot Financial Group Insurance Agency LLC boosted its position in Nymox Pharmaceutical by 48.1% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 34,650 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 11,250 shares during the period. 1.09% of the stock is owned by institutional investors and hedge funds.

About Nymox Pharmaceutical

(Get Rating)

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.